Compare · COSM vs MCK
COSM vs MCK
Side-by-side comparison of Cosmos Health Inc. (COSM) and McKesson Corporation (MCK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COSM and MCK operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $94.27B, about 7041.0x COSM ($13.4M).
- Over the past year, COSM is down 97.9% and MCK is up 11.2% - MCK leads by 109.1 points.
- MCK has been more active in the news (35 items in the past 4 weeks vs 15 for COSM).
- MCK has more recent analyst coverage (25 ratings vs 0 for COSM).
- Company
- Cosmos Health Inc.
- McKesson Corporation
- Price
- $0.21-8.66%
- $785.02+0.09%
- Market cap
- $13.4M
- $94.27B
- 1M return
- -33.70%
- +8.38%
- 1Y return
- -97.87%
- +11.24%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 15
- 35
- Recent ratings
- 0
- 25
Cosmos Health Inc.
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest COSM
- Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway
- Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN
- Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives
- Amendment: SEC Form S-3/A filed by Cosmos Health Inc.
- SEC Form DEFA14A filed by Cosmos Health Inc.
- Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz
- Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value
- SEC Form DEF 14A filed by Cosmos Health Inc.
- Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajectory; Notes No Known Business Reason for Recent Share Price Decline
- Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation
Latest MCK
- SVP, Controller & CAO Rutledge Napoleon B Jr sold $101,612 worth of shares (133 units at $764.00) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 632 units (SEC Form 4)
- EVP, Chief Strategy & BDO Rodgers Thomas L sold $604,420 worth of shares (822 units at $735.30) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 2,268 units (SEC Form 4)
- EVP & Chief HR Officer Smith Leann B sold $1,331,255 worth of shares (1,810 units at $735.50) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 4,798 units (SEC Form 4)
- McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions
- SEC Form 4 filed by EVP & CFO Cheung Kenny K
- SEC Form 3 filed by new insider Cheung Kenny K
- SEC Form SD filed by McKesson Corporation
- EVP and Chief Legal Officer Lau Michele sold $2,701,870 worth of shares (3,550 units at $761.09) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 3,247 units (SEC Form 4)
- EVP & CFO Vitalone Britt J. converted options into 1,476 shares and covered exercise/tax liability with 581 shares, increasing direct ownership by 4% to 21,953 units (SEC Form 4)
- Chief Executive Officer Tyler Brian S. converted options into 4,579 shares and covered exercise/tax liability with 1,831 shares, increasing direct ownership by 11% to 27,774 units (SEC Form 4)